Russell S. Scott

Christchurch, CAN, New Zealand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310.

Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310.

Journal: The New England journal of medicine

Published: August 28, 2026

In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.

In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.

Journal: The New England journal of medicine

Published: May 26, 2026

Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.

Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.

Journal: JAMA cardiology

Published: April 29, 2026

Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudy.

Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudy.

Journal: Diabetes research and clinical practice

Published: December 19, 2025

Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.

Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.

Journal: The New England journal of medicine

Published: November 10, 2025

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

Journal: JAMA

Published: November 09, 2025

Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial.

Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial.

Journal: Nature medicine

Published: July 02, 2025

The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study.

The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study.

Journal: European journal of preventive cardiology

Published: February 03, 2025

Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudy.

Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudy.

Journal: Diabetes research and clinical practice

Published: December 24, 2024

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.

Journal: JAMA cardiology

Published: July 03, 2024

A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.

A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.

Journal: Kidney international

Published: April 19, 2024

Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate.

Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate.

Journal: Journal of diabetes investigation

Published: March 16, 2024

Showing 1-12 of 41

Last Updated: 09/26/2026